Inhibition of Hepatitis B Virus Replication by Nucleoside Enantiomers of β-2′,3′-Dideoxypurine Analogues
Open Access
- 1 October 1996
- journal article
- research article
- Published by SAGE Publications in Antiviral Chemistry and Chemotherapy
- Vol. 7 (5) , 276-280
- https://doi.org/10.1177/095632029600700508
Abstract
Various purine β-L-2′,3′-dideoxynucleoside analogues with both sugar and base modifications including β-L-ddG, β-L-ddl, β-L-ddA, 2′-azido-β-L-araddA, 2′-amino-β-L-araddA, 2′,5′-anhydro-β-L-araddA, 2′-azido-β-L-ddA, 2′-amino-β-L-ddA, 2′-fluoro-β-L-ddA, 3′-azido-β-L-ddA, 3′-amino-β-L-ddA, 3′-fluoro-β-L-ddA, 2,6-diamino-β-L-2′,3′-dideoxyfuranosylpurine, 6-cyclopropylamino-β-L-ddA, 2′-azido-6-N-triphenylphosphine-β-L-araddA, 2-amino-6-methylamino-β-L-2′,3′-dideoxyfuranosylpurine, 2-amino-6-cyclopropylamino-β-L-2′,3′-dideoxyfuranosylpurine, 2-amino-6-cyclopentylamino-β-L-2′,3′-dideoxyfuranosylpurine, 2′,3′-didehydro-β-L-ddA and 2′,3′-didehydro-6-N-triphenyl phosphine-β-L-ddA were synthesized and evaluated as potential inhibitors of hepatitis B virus (HBV) replication in HBV DNA-transfected human hepatoblastoma-derived Hep-G2 cells (2.2.15 cells). β-L-ddA, 2′-azido-β-L-ddA, 3′-azido-β-L-ddA, 2″,3′-didehydro-β-L-ddA (β-L-D4A) and a modified base of β-L-D4A, inhibited HBV replication in vitro. β-L-D4A was the more potent and selective antiHBV agent with a 50% effective concentration value of 0.1 μM and a selectivity index of 1800. On the basis of this finding, studies are in progress to synthesize new purine derivatives with the β-L unnatural configuration which hopefully will lead to identifying additional potent and highly selective anti-HBV agents.Keywords
This publication has 21 references indexed in Scilit:
- Synthesis of a Series of Purine 2′,3′-Dideoxy-L-Nucleoside Analogues as Potential Antiviral AgentsNucleosides and Nucleotides, 1995
- Treatment of hepatitis B by nucleoside analogs: still a realityCurrent Opinion in Infectious Diseases, 1994
- The in vitro anti-hepatitis B virus activity of FIAU [1-(2′-deoxy-2′-fluoro-1-β-d-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cellAntiviral Research, 1994
- Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replicationAntiviral Research, 1992
- (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitroAntimicrobial Agents and Chemotherapy, 1992
- Inhibition of duck hepatitis B virus replication by purine 2′,3′-dideoxynucleosidesBiochemical and Biophysical Research Communications, 1988
- PHASE I STUDIES OF 2',3'-DIDEOXYCYTIDINE IN SEVERE HUMAN IMMUNODEFICIENCY VIRUS INFECTION AS A SINGLE AGENT AND ALTERNATING WITH ZIDOVUDINE (AZT)The Lancet, 1988
- Interferon in viral hepatitis: Role in pathogenesis and treatmentHepatology, 1986
- Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediatePublished by Elsevier ,1982
- HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUSThe Lancet, 1981